{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6286","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"11.8","value":"7.7"},{"groupId":"OG001","lowerLimit":"4.9","upperLimit":"13.5","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"NUMBER","populationDescription":"Pain Response (applies only to patients, in the Intention-To-Treat (ITT) population, with median PPI ≥2 on McGill-Melzack scale and/or mean Analgesic Score ≥10 points at baseline)","reportingStatus":"POSTED","timeFrame":"from baseline up to 104 weeks (study cut-off)","title":"Pain Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}